Neulasta (Pegfilgrastim) - Summary

NEULASTA SUMMARY

Neulasta^®
(pegfilgrastim)

Neulasta™ (pegfilgrastim) is a covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol.

Neulasta™ is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

NEULASTA NEWS HIGHLIGHTS

Published Studies Related to Neulasta (Pegfilgrastim)

Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. [2007.09]

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. [2007.07]

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. [2006.11]

Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. [2006.04]

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. [2005.02.20]

more>>

Clinical Trials Related to Neulasta (Pegfilgrastim)

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma [Completed]

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer [Active, not recruiting]

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy [Completed]

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim (Neulasta) in Subjects With Advanced Colon Cancer [Active, not recruiting]

Pegfilgrastim PBPC Mobilization Study [Completed]

more>>